ClinicalTrials.gg
TerminatedNCT00427934Updated Nov 5, 2014Results posted

Maraviroc in Rheumatoid Arthritis

A Phase 2 interventional study of Maraviroc and Maraviroc Placebo in Arthritis, Rheumatoid, sponsored by Pfizer. Terminated at 44 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-05.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Why this study was terminated
See Detailed Description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 152 studies in Arthritis, Rheumatoid by Pfizer — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Pfizer.

Enrollment
48th of 86
128 · median 155
Started
2007
with 12 others
Phase 2
28 of 152
none open now
Registered
23rd of 152
by date

Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 48th largest by enrollment of the 86 interventional ones that give a count, is one of 13 that started in 2007, is one of 28 in phase 2, and was the 23rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 152 studies in Arthritis, Rheumatoid by Pfizer are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Arthritis, Rheumatoid by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether maraviroc, an investigational drug given with methotrexate (MTX) is safe and effective in the treatment of rheumatoid arthritis in adult patients.

Read the detailed description

Following a planned interim analysis in the POC component on 21 August 2008 by the internal DMC (Data Monitoring Committee) of study A4001056, the trial was discontinued due to lack of efficacy. All participating investigators/country offices and monitors were notified on 22 August 2008 to cease patient enrollment. The DMC indicated that maraviroc was well tolerated in the Rheumatoid Arthritis patients and there were no safety concerns in the study. The termination date of this trial was 07 October 2008 when the last patient last visit occurred.

03

Conditions studied

  • Arthritis, Rheumatoid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be legal age of consent
  • Must have active rheumatoid arthritis based upon the American College of Rheumatology (ACR) 1987 (Revised Criteria); minimum disease criteria required for entry into the efficacy component of the study
  • Must meet ACR 1991 Revised Criteria for Global Functional Status in RA, Class I, II, or III
  • Must be receiving methotrexate for at least 12 weeks duration and on a stable dose for 4 weeks.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with any other inflammatory arthritis or a secondary non-inflammatory arthritis that would interfere with disease activity assessments.
  • Subject receiving prior treatment with certain medications for rheumatoid arthritis
  • Tuberculosis and/or a positive tuberculin reaction
  • Significant trauma or major surgery within 2 months
  • History of alcohol and/or drug abuse outside of a defined period of abstinence
  • History of or a finding at screening of postural hypotension
  • Any condition that would affect the oral absorption of the drug
  • History of cancer and in remission less than 3 years or Grade III-IV congestive heart failure
  • Having an infection of (HIV), or C or evidence of any active infection
  • Abnormalities of clinical or laboratory assessments completed at the screening visit such as elevated liver enzymes, decreased or an abnormal
  • Having a positive chemokine receptor 5 (CCR5) delta 32 mutation
  • Requiring the use of certain medications
  • Lactating or pregnant women or subjects have unwilling to use an adequate method of
  • Chronic or recent serious or life-threatening infection; severe , progressive and/or uncontrollable renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological disease within 12 weeks of the first dose.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
128 participants (actual)

Study arms

  • Placebo comparator
    2

    Drug: Maraviroc Placebo

  • Experimental
    1

    This study was divided into two components: safety/pharmacokinetic (PK) and proof-of-concept (POC). In the safety/PK component either 150 mg or 300 mg tablets of maraviroc was administered twice a day (BID) to 16 rheumatoid arthritis subjects for 4 weeks.

    Drug: Maraviroc

Interventions

  • 300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.

  • DrugMaraviroc Placebo

    Placebo tablets to match active drug. Two tablets are administered by mouth twice a day (BID) for 12 weeks.

06

What researchers measure

Primary outcomes

  1. American College of Rheumatology (ACR) 20% Responders at Week 12

    A subject was an ACR 20 responder if: the counts for both tender and swollen joints had reduced by 20% or more from baseline; and 3 out of the following 5 assessments showed reduction of 20% or more from baseline assessment: Patient's Assessment of Arthritis Pain (Visual Analogue Scale \[VAS\]), Patient's Global Assessment of Arthritis (VAS), Physician's Global Assessment of Arthritis (Categorical), Health Assessment Questionnaire - Disability Index (HAQ-DI), and C-Reactive Protein (CRP).

    Time frame: Week 12

Secondary outcomes

  1. ACR 20% Responders at Weeks 1, 2, 4, and 8

    A subject was an ACR 20 responder if: the counts for both tender and swollen joints had reduced by 20% or more from baseline; and 3 out of the following 5 assessments showed reduction of 20% or more from baseline assessment: Patient's Assessment of Arthritis Pain, Patient's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, HAQ-DI, and CRP. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 ACR 20% data were collected, but not analyzed.

    Time frame: Weeks 1, 2, 4, and 8

  2. ACR 50% Responders at Weeks 1, 2, 4, 8, and 12

    A subject was an ACR 50 responder if: the counts for both tender and swollen joints had reduced by 50% or more from baseline; and 3 out of the following 5 assessments showed reduction of 50% or more from baseline assessment: Patient's Assessment of Arthritis Pain, Patient's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, HAQ-DI, and CRP. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 ACR 50% data were collected, but not analyzed.

    Time frame: Weeks 1, 2, 4, 8, and 12

  3. ACR 70% Responders at Weeks 1, 2, 4, 8, and 12

    A subject was an ACR 70 responder if: the counts for both tender and swollen joints had reduced by 70% or more from baseline; and 3 out of the following 5 assessments showed reduction of 70% or more from baseline assessment: Patient's Assessment of Arthritis Pain, Patient's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, HAQ-DI, and CRP. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 ACR 70% data were collected, but not analyzed.

    Time frame: Weeks 1, 2, 4, 8, and 12

  4. Change From Baseline in Tender/Painful Joint Count at Weeks 1, 2, 4, 8, and 12

    Change from baseline at each visit was analyzed for tender/painful joint count. Twenty-eight tender and swollen joint scores included the same joints: shoulders, elbows, wrists, metacarpophalangeal joints (MCP), proximal interphalangeal joints (PIP), and the knees. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 tender/painful joint count data were collected, but not analyzed.

    Time frame: Baseline, Weeks 1, 2, 4, 8, and 12

  5. Change From Baseline in Swollen Joint Count at Weeks 1, 2, 4, 8, and 12

    Change from baseline at each visit was analyzed for swollen joint count. Twenty-eight tender and swollen joint scores included the same joints: shoulders, elbows, wrists, MCP joints, PIP joints, and the knees. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 swollen joint count data were collected, but not analyzed.

    Time frame: Baseline, Weeks 1, 2, 4, 8, and 12

  6. Change From Baseline in Patient's Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12

    The severity of arthritis was scored by the subject between 0 (no pain) and 100 (most severe pain) on a 100 mm VAS. Change from baseline at each visit was analyzed for Patient's Assessment of Arthritis Pain. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 Patient's Assessment of Arthritis Pain data were collected, but not analyzed.

    Time frame: Baseline, Weeks 1, 2, 4, 8, and 12

  7. Change From Baseline in Patient's Global Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12

    Subjects answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Subjects responded by using a 0 - 100 mm VAS where 0=very well and 100=very poorly. Change from baseline at each visit was analyzed for Patient's Global Assessment. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 Patient's Global Assessment of Arthritis Pain data were collected, but not analyzed.

    Time frame: Baseline, Weeks 1, 2, 4, 8, and 12

  8. Change From Baseline in Physician's Global Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12

    Physician's evaluation based on subject's disease signs, functional capacity and physical exam. Response recorded using 5-point scale: 1=Very Good, 2=Good, 3=Fair, 4=Poor and 5=Very Poor. Change from baseline at each visit was analyzed for Physician's Global Assessment. The Week 16 visit (follow-up) was designed for safety rather than efficacy thus Week 16 Physician's Global Assessment of Arthritis Pain data were collected but not analyzed.

    Time frame: Baseline, Weeks 1, 2, 4, 8, and 12

  9. Change From Baseline in HAQ-DI at Weeks 1, 2, 4, 8, and 12

    HAQ-DI assesses degree of difficulty experienced in daily activity categories (dressing/grooming, arising, eating, walking, hygiene, reach, grip and other activities) over the past week. There are 20 questions and difficulty is scored from 0 (none), 1 (some), 2 (much) and 3 (unable to do). Scores were then averaged to give the disability index (scale of 0 to 3). Change from baseline at each visit was analyzed. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 HAQ-DI data were collected but not analyzed.

    Time frame: Baseline, Weeks 1, 2, 4, 8, and 12

  10. Change From Baseline in CRP at Weeks 1, 2, 4, 8, and 12

    Change from baseline at each visit were analyzed for CRP. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 CRP data were collected, but not analyzed.

    Time frame: Baseline, Weeks 1, 2, 4, 8, and 12

  11. Change From Baseline in Disease Activity Score Using CRP (DAS28-4[CRP]) at Weeks 1, 2, 4, 8, and 12

    DAS28-4 (CRP) was calculated using the following formula: DAS28- 4(CRP) = 0.56 √28 Tender Joint Count + 0.28 √28 Swollen Joint Count + 0.36\*natural logarithm(CRP + 1) + 0.014\*Patient Global Assessment + 0.96. DAS28 provides a number on a scale (0 to 10) indicating current disease activity. A score above 5.1 means high disease activity and a score below 3.2 indicates low disease activity. Change from baseline at each visit was analyzed for DAS28-4 (CRP). The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 DAS28-4 (CRP) data were collected, but not analyzed.

    Time frame: Baseline, Weeks 1, 2, 4, 8, and 12

  12. Change From Baseline in Mean Orthostatic Blood Pressure (BP)

    Supine BP was recorded after 5 minutes lying down; subjects then sat for 2 minutes then stood for 2 minutes and standing BP was recorded. Orthostatic BP = either a systolic BP drop \> 20 mmHg, or diastolic BP drop \> 10 mmHg and/or drop in systolic BP \< 90 mmHg. If a subject met the orthostatic criteria, they were required to complete 2 additional readings to provide a triplicate reading. The means of replicate BP values were used in the analysis. Baseline = the latest non-missing value from a range of pre-treatment visits. Change from baseline to Week 16 was analyzed for orthostatic BP.

    Time frame: Baseline, 16 weeks

  13. Change From Baseline in Mean Heart Rate

    Heart rate = standing and supine at the same time the orthostatic BP measurements were obtained. Baseline was defined to be the latest non-missing value from a range of pre-treatment visits. Means of replicate values were not used.

    Time frame: Baseline, 16 weeks

  14. Number of Subjects With Categorical Absolute Vital Signs and Vital Sign Changes Compared to Baseline

    Baseline was defined to be the latest non-missing value from a range of pre-treatment visits. Maximum increase from baseline in supine and standing systolic BP was \> = 30 mmHg, and maximum increase from baseline in supine and standing diastolic BP was \> = 20 mmHg.

    Time frame: Baseline, 16 weeks

  15. Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (RR Interval, PR Interval, QRS Complex, QT Interval, Corrected QT [QTc] Interval, QTcB Interval [Bazett's Correction], QTcF Interval [Fridericia's Correction]).

    Baseline was defined to be the latest non-missing value from a range of pre-treatment visits. Means of replicate values were used. QTc interval was not measured for the PK populations.

    Time frame: Baseline, 16 weeks

  16. Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (Heart Rate).

    Baseline was defined to be the latest non-missing value from a range of pre-treatment visits. Means of replicate values were used.

    Time frame: Baseline, 16 weeks

  17. Number of Subjects With Categorical Absolute ECG Parameters and ECG Changes Compared to Baseline

    Maximum QTcB, QTcF, and QTc intervals were defined as 450 to \< 480 msec, 480 to \< 500 msec, or \> = 500 msec.

    Time frame: Baseline, 16 weeks

  18. Change From Baseline in Short Form-36 (SF-36) Physical Component Summary at Weeks 4 and 12

    The SF-36 v.2 (Acute version) is a 36-item generic health status measure that measures 8 general health concepts: Physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Each domain of the eight domains and the summary concept (physical component score) are scored to yield values between 0 (worst) and 100 (best). Change from baseline at Weeks 4 and 12 were analyzed for SF-36. Due to the termination of the study, SF-36 results for the PK component group were not analyzed.

    Time frame: Baseline, Weeks 4 and 12

  19. Change From Baseline in SF-36 Mental Component Summary at Weeks 4 and 12

    The SF-36 v.2 (Acute version) \[12\] is a 36-item generic health status measure that measures 8 general health concepts: Physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Each domain of the eight domains and the summary concept (mental component score) are scored to yield values between 0 (worst) and 100 (best). Change from baseline at Weeks 4 and 12 were analyzed for SF-36. Due to the termination of the study, SF-36 results for the PK component group were not analyzed.

    Time frame: Baseline, Weeks 4 and 12

  20. Number of Subjects With Withdrawal From Study Due to Lack of Efficacy

    Withdrawal is the total number of withdrawals from the study. Withdrawal due to lack of efficacy was collected based on the investigator's judgement.

    Time frame: 16 weeks

  21. Survival Analysis of Time to Withdrawal: Proportion of Subjects Who Did Not Withdraw From the Study Due to Lack of Efficacy.

    Withdrawal due to lack of efficacy was collected based on the investigator's judgement. Time to withdrawal was measured by the probability that a subject did not withdraw due to lack of efficacy by a particular visit. This was a statistical estimate (Kaplan-Meier Survival Analysis) of the probability that a participant would not withdraw due to lack of efficacy.

    Time frame: Weeks 1 to 12

  22. Area Under the Plasma Concentration-Time Profile From Time Zero to Four Hours Postdose (AUC 0-4) for MTX at Screening and Week 1 and Maraviroc at Week 1

    Effect of maraviroc on the PK of MTX (comparison of AUC0-4 of MTX at screening versus at Week 1 after coadministration with 150 mg or 300 mg of maraviroc). PK was assessed at screening (MTX) and at Week 1 (maraviroc and MTX).

    Time frame: Screening (1, 2, 3, and 4 hours post-dose), Week 1 (0.5, 1, 2, 3, and 4 hours post-dose)

  23. Maximum Observed Concentration (Cmax) During the Dosing Interval for MTX at Screening and Week 1 and Maraviroc at Week 1

    Effect of maraviroc on the PK of MTX (comparison of Cmax of MTX at screening versus at Week 1 after coadministration with 150 mg or 300 mg of maraviroc). PK was assessed at screening (MTX) and at Week 1 (maraviroc and MTX).

    Time frame: Screening (1, 2, 3, and 4 hours post-dose), Week 1 (0.5, 1, 2, 3, and 4 hours post-dose)

  24. Time for Cmax (Tmax) for MTX at Screening and Week 1 and Maraviroc at Week 1

    PK was assessed at screening (MTX) and at Week 1 (maraviroc and MTX).

    Time frame: Screening (1, 2, 3, and 4 hours post-dose), Week 1 (0.5, 1, 2, 3, and 4 hours post-dose)

07

Results

Posted Feb 5, 2010

Participant flow

Participant flow — Overall Study
MilestoneMaraviroc 150 mg BID (Pharmacokinetic [PK])Maraviroc 300 mg BID (PK)Maraviroc 300 mg BID (Proof-of-Concept [POC])Placebo (POC)
Started887834
Treated887733
Completed785519
Not completed102315
Withdrew: Adverse event1054
Withdrew: Lack of efficacy0052
Withdrew: Randomized but did not receive treatment0011
Withdrew: Other00115
Withdrew: Withdrawal by subject0013

Outcome measures

SecondaryACR 20% Responders at Weeks 1, 2, 4, and 8

A subject was an ACR 20 responder if: the counts for both tender and swollen joints had reduced by 20% or more from baseline; and 3 out of the following 5 assessments showed reduction of 20% or more from baseline assessment: Patient's Assessment of Arthritis Pain, Patient's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, HAQ-DI, and CRP. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 ACR 20% data were collected, but not analyzed.

Time frame:
Weeks 1, 2, 4, and 8
Reported as:
Number · Participants
ACR 20% Responders at Weeks 1, 2, 4, and 8
ParticipantsMaraviroc 300 mg BID (POC)Placebo (POC)
Week 184
Week 2125
Week 4218
Week 8237
Statistical analysis
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · Barnard/Pearson chi-square test · p = 0.790 · Percentage difference: -1.73 · 90% CI -15.13 to 8.68Percentage Difference = maraviroc responders divided by the number of maraviroc participants analyzed minus placebo responders divided by the number of placebo participants analyzed.
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · Barnard/Pearson chi-square test · p = 0.477 · Percentage difference: 0.43 · 90% CI -13.67 to 11.64Percentage Difference = maraviroc responders divided by the number of maraviroc participants analyzed minus placebo responders divided by the number of placebo participants analyzed.
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · Barnard/Pearson chi-square test · p = 0.370 · Percentage difference: 3.03 · 90% CI -12.85 to 16.77Percentage Difference = maraviroc responders divided by the number of maraviroc participants analyzed minus placebo responders divided by the number of placebo participants analyzed.
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · Barnard/Pearson chi-square test · p = 0.175 · Percentage difference: 8.66 · 90% CI -7.07 to 22.03Percentage Difference = maraviroc responders divided by the number of maraviroc participants analyzed minus placebo responders divided by the number of placebo participants analyzed.
SecondaryACR 50% Responders at Weeks 1, 2, 4, 8, and 12

A subject was an ACR 50 responder if: the counts for both tender and swollen joints had reduced by 50% or more from baseline; and 3 out of the following 5 assessments showed reduction of 50% or more from baseline assessment: Patient's Assessment of Arthritis Pain, Patient's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, HAQ-DI, and CRP. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 ACR 50% data were collected, but not analyzed.

Time frame:
Weeks 1, 2, 4, 8, and 12
Reported as:
Number · Participants
ACR 50% Responders at Weeks 1, 2, 4, 8, and 12
ParticipantsMaraviroc 300 mg BID (POC)Placebo (POC)
Week 110
Week 220
Week 422
Week 863
Week 1283
Statistical analysis
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · Barnard/Pearson chi-square test · p = 0.420 · Percentage difference: 1.30 · 90% CI -6.34 to 6.01Percentage Difference = maraviroc responders divided by the number of maraviroc participants analyzed minus placebo responders divided by the number of placebo participants analyzed.
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · Barnard/Pearson chi-square test · p = 0.258 · Percentage difference: 2.60 · 90% CI -5.08 to 7.95Percentage Difference = maraviroc responders divided by the number of maraviroc participants analyzed minus placebo responders divided by the number of placebo participants analyzed.
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · Barnard/Pearson chi-square test · p = 1.000 · Percentage difference: -3.46 · 90% CI -14.39 to 3.42Percentage Difference = maraviroc responders divided by the number of maraviroc participants analyzed minus placebo responders divided by the number of placebo participants analyzed.
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · Barnard/Pearson chi-square test · p = 0.899 · Percentage difference: -1.30 · 90% CI -13.56 to 7.92Percentage Difference = maraviroc responders divided by the number of maraviroc participants analyzed minus placebo responders divided by the number of placebo participants analyzed.
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · Barnard/Pearson chi-square test · p = 0.489 · Percentage difference: 1.30 · 90% CI -11.24 to 10.96Percentage Difference = maraviroc responders divided by the number of maraviroc participants analyzed minus placebo responders divided by the number of placebo participants analyzed.
SecondaryACR 70% Responders at Weeks 1, 2, 4, 8, and 12

A subject was an ACR 70 responder if: the counts for both tender and swollen joints had reduced by 70% or more from baseline; and 3 out of the following 5 assessments showed reduction of 70% or more from baseline assessment: Patient's Assessment of Arthritis Pain, Patient's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, HAQ-DI, and CRP. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 ACR 70% data were collected, but not analyzed.

Time frame:
Weeks 1, 2, 4, 8, and 12
Reported as:
Number · Participants
ACR 70% Responders at Weeks 1, 2, 4, 8, and 12
ParticipantsMaraviroc 300 mg BID (POC)Placebo (POC)
Week 100
Week 200
Week 401
Week 820
Week 1201
Statistical analysis
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · Barnard/Pearson chi-square test · p = 1.000 · Percentage difference: -3.03 · 90% CI -13.59 to 1.28Percentage Difference = maraviroc responders divided by the number of maraviroc participants analyzed minus placebo responders divided by the number of placebo participants analyzed.
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · Barnard/Pearson chi-square test · p = 0.258 · Percentage difference: 2.60 · 90% CI -5.08 to 7.95Percentage Difference = maraviroc responders divided by the number of maraviroc participants analyzed minus placebo responders divided by the number of placebo participants analyzed.
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · Barnard/Pearson chi-square test · p = 1.000 · Percentage difference: -3.03 · 90% CI -13.59 to 1.28Percentage Difference = maraviroc responders divided by the number of maraviroc participants analyzed minus placebo responders divided by the number of placebo participants analyzed.
SecondaryChange From Baseline in Tender/Painful Joint Count at Weeks 1, 2, 4, 8, and 12

Change from baseline at each visit was analyzed for tender/painful joint count. Twenty-eight tender and swollen joint scores included the same joints: shoulders, elbows, wrists, metacarpophalangeal joints (MCP), proximal interphalangeal joints (PIP), and the knees. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 tender/painful joint count data were collected, but not analyzed.

Time frame:
Baseline, Weeks 1, 2, 4, 8, and 12
Reported as:
Least squares mean · joint count
Change From Baseline in Tender/Painful Joint Count at Weeks 1, 2, 4, 8, and 12
joint countMaraviroc 300 mg BID (POC)Placebo (POC)
Week 1-0.81 ± 0.68-1.91 ± 0.96
Week 2-2.08 ± 0.76-2.38 ± 1.08
Week 4-4.00 ± 0.84-4.01 ± 1.20
Week 8-4.85 ± 0.85-3.24 ± 1.21
Week 12-4.89 ± 0.84-3.41 ± 1.19
Statistical analysis
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.335 (This analysis was carried out using analysis of covariance (ANCOVA) with baseline tender/painful joint count as the covariate, treatment, region as fixed effects.) · Mean difference (final values): 1.10 · 90% CI -0.79 to 2.99
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.816 (This analysis was carried out using ANCOVA with baseline tender/painful joint count as the covariate, treatment, region as fixed effects.) · Mean difference (final values): 0.30 · 90% CI -1.82 to 2.41
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.996 (This analysis was carried out using ANCOVA with baseline tender/painful joint count as the covariate, treatment, region as fixed effects.) · Median difference (final values): 0.01 · 90% CI -2.35 to 2.36
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.263 (This analysis was carried out using ANCOVA with baseline tender/painful joint count as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -1.61 · 90% CI -3.98 to 0.76
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.294 (This analysis was carried out using ANCOVA with baseline tender/painful joint count as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -1.48 · 90% CI -3.82 to 0.85
SecondaryChange From Baseline in Swollen Joint Count at Weeks 1, 2, 4, 8, and 12

Change from baseline at each visit was analyzed for swollen joint count. Twenty-eight tender and swollen joint scores included the same joints: shoulders, elbows, wrists, MCP joints, PIP joints, and the knees. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 swollen joint count data were collected, but not analyzed.

Time frame:
Baseline, Weeks 1, 2, 4, 8, and 12
Reported as:
Least squares mean · joint count
Change From Baseline in Swollen Joint Count at Weeks 1, 2, 4, 8, and 12
joint countMaraviroc 300 mg BID (POC)Placebo (POC)
Week 1-1.39 ± 0.49-1.07 ± 0.70
Week 2-2.25 ± 0.61-2.51 ± 0.87
Week 4-3.93 ± 0.54-4.08 ± 0.77
Week 8-4.48 ± 0.62-3.03 ± 0.88
Week 12-3.48 ± 0.66-3.43 ± 0.95
Statistical analysis
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.700 (This analysis was carried out using ANCOVA baseline swollen joint count as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -0.32 · 90% CI -1.70 to 1.06
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.799 (This analysis was carried out using ANCOVA baseline swollen joint count as the covariate, treatment, region as fixed effects.) · Mean difference (final values): 0.26 · 90% CI -1.45 to 1.97
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.867 (This analysis was carried out using ANCOVA baseline swollen joint count as the covariate, treatment, region as fixed effects.) · Mean difference (final values): 0.15 · 90% CI -1.35 to 1.66
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.167 (This analysis was carried out using ANCOVA baseline swollen joint count as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -1.45 · 90% CI -3.17 to 0.28
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.966 (This analysis was carried out using ANCOVA baseline swollen joint count as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -0.05 · 90% CI -1.91 to 1.81
SecondaryChange From Baseline in Patient's Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12

The severity of arthritis was scored by the subject between 0 (no pain) and 100 (most severe pain) on a 100 mm VAS. Change from baseline at each visit was analyzed for Patient's Assessment of Arthritis Pain. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 Patient's Assessment of Arthritis Pain data were collected, but not analyzed.

Time frame:
Baseline, Weeks 1, 2, 4, 8, and 12
Reported as:
Least squares mean · scores on scale
Change From Baseline in Patient's Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12
scores on scaleMaraviroc 300 mg BID (POC)Placebo (POC)
Week 1-3.96 ± 2.18-3.62 ± 3.10
Week 2-8.46 ± 2.65-3.20 ± 3.77
Week 4-8.35 ± 2.70-9.08 ± 3.85
Week 8-10.30 ± 2.98-8.67 ± 4.24
Week 12-8.30 ± 2.85-6.09 ± 4.06
Statistical analysis
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.925 (This analysis was carried out using ANCOVA with baseline patient's assessment of arthritis pain as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -0.34 · 90% CI -6.41 to 5.72
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.239 (This analysis was carried out using ANCOVA with baseline patient's assessment of arthritis pain as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -5.26 · 90% CI -12.62 to 2.11
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.872 (This analysis was carried out using ANCOVA with baseline patient's assessment of arthritis pain as the covariate, treatment, region as fixed effects.) · Mean difference (final values): 0.73 · 90% CI -6.79 to 8.25
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.745 (This analysis was carried out using ANCOVA with baseline patient's assessment of arthritis pain as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -1.63 · 90% CI -9.91 to 6.65
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.644 (This analysis was carried out using ANCOVA with baseline patient's assessment of arthritis pain as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -2.22 · 90% CI -10.14 to 5.71
SecondaryChange From Baseline in Patient's Global Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12

Subjects answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Subjects responded by using a 0 - 100 mm VAS where 0=very well and 100=very poorly. Change from baseline at each visit was analyzed for Patient's Global Assessment. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 Patient's Global Assessment of Arthritis Pain data were collected, but not analyzed.

Time frame:
Baseline, Weeks 1, 2, 4, 8, and 12
Reported as:
Least squares mean · scores on scale
Change From Baseline in Patient's Global Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12
scores on scaleMaraviroc 300 mg BID (POC)Placebo (POC)
Week 1-4.70 ± 2.22-2.34 ± 3.13
Week 2-8.85 ± 2.48-4.88 ± 3.49
Week 4-10.00 ± 2.74-9.02 ± 3.86
Week 8-11.12 ± 2.93-3.44 ± 4.13
Week 12-8.55 ± 2.88-6.78 ± 4.06
Statistical analysis
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.524 (This analysis was carried out using ANCOVA with baseline Patient's Global Assessment of Arthritis as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -2.36 · 90% CI -8.49 to 3.77
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.338 (This analysis was carried out using ANCOVA with baseline Patient's Global Assessment of Arthritis as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -3.96 · 90% CI -10.80 to 2.87
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.830 (This analysis was carried out using ANCOVA with baseline Patient's Global Assessment of Arthritis as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -0.98 · 90% CI -8.55 to 6.58
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.118 (This analysis was carried out using ANCOVA with baseline Patient's Global Assessment of Arthritis as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -7.68 · 90% CI -15.76 to 0.40
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.712 (This analysis was carried out using ANCOVA with baseline Patient's Global Assessment of Arthritis as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -1.78 · 90% CI -9.73 to 6.18
SecondaryChange From Baseline in Physician's Global Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12

Physician's evaluation based on subject's disease signs, functional capacity and physical exam. Response recorded using 5-point scale: 1=Very Good, 2=Good, 3=Fair, 4=Poor and 5=Very Poor. Change from baseline at each visit was analyzed for Physician's Global Assessment. The Week 16 visit (follow-up) was designed for safety rather than efficacy thus Week 16 Physician's Global Assessment of Arthritis Pain data were collected but not analyzed.

Time frame:
Baseline, Weeks 1, 2, 4, 8, and 12
Reported as:
Least squares mean · scores on scale
Change From Baseline in Physician's Global Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12
scores on scaleMaraviroc 300 mg BID (POC)Placebo (POC)
Week 1-0.30 ± 0.08-0.22 ± 0.11
Week 2-0.44 ± 0.09-0.39 ± 0.12
Week 4-0.49 ± 0.10-0.44 ± 0.13
Week 8-0.63 ± 0.10-0.37 ± 0.14
Week 12-0.49 ± 0.11-0.36 ± 0.15
Statistical analysis
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.540 (This analysis was carried out using ANCOVA with baseline Physician's Global Assessment of Arthritis as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -0.08 · 90% CI -0.28 to 0.13
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.757 (This analysis was carried out using ANCOVA with baseline Physician's Global Assessment of Arthritis as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -0.04 · 90% CI -0.28 to 0.19
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.767 (This analysis was carried out using ANCOVA with baseline Physician's Global Assessment of Arthritis as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -0.05 · 90% CI -0.31 to 0.21
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.112 (This analysis was carried out using ANCOVA with baseline Physician's Global Assessment of Arthritis as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -0.26 · 90% CI -0.52 to 0.01
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.490 (This analysis was carried out using ANCOVA with baseline Physician's Global Assessment of Arthritis as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -0.13 · 90% CI -0.42 to 0.17
SecondaryChange From Baseline in HAQ-DI at Weeks 1, 2, 4, 8, and 12

HAQ-DI assesses degree of difficulty experienced in daily activity categories (dressing/grooming, arising, eating, walking, hygiene, reach, grip and other activities) over the past week. There are 20 questions and difficulty is scored from 0 (none), 1 (some), 2 (much) and 3 (unable to do). Scores were then averaged to give the disability index (scale of 0 to 3). Change from baseline at each visit was analyzed. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 HAQ-DI data were collected but not analyzed.

Time frame:
Baseline, Weeks 1, 2, 4, 8, and 12
Reported as:
Least squares mean · scores on scale
Change From Baseline in HAQ-DI at Weeks 1, 2, 4, 8, and 12
scores on scaleMaraviroc 300 mg BID (POC)Placebo (POC)
Week 1-0.08 ± 0.05-0.03 ± 0.07
Week 2-0.22 ± 0.06-0.04 ± 0.08
Week 4-0.24 ± 0.06-0.18 ± 0.09
Week 8-0.25 ± 0.07-0.03 ± 0.10
Week 12-0.18 ± 0.08-0.06 ± 0.13
Statistical analysis
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.464 (This analysis was carried out using ANCOVA with HAQ-DI as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -0.06 · 90% CI -0.19 to 0.07
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.068 (This analysis was carried out using ANCOVA with HAQ-DI as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -0.18 · 90% CI -0.35 to -0.02
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.532 (This analysis was carried out using ANCOVA with HAQ-DI as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -0.06 · 90% CI -0.23 to 0.11
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.063 (This analysis was carried out using ANCOVA with HAQ-DI as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -0.22 · 90% CI -0.41 to -0.03
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.396 (This analysis was carried out using ANCOVA with HAQ-DI as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -0.12 · 90% CI -0.36 to 0.12
SecondaryChange From Baseline in CRP at Weeks 1, 2, 4, 8, and 12

Change from baseline at each visit were analyzed for CRP. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 CRP data were collected, but not analyzed.

Time frame:
Baseline, Weeks 1, 2, 4, 8, and 12
Reported as:
Least squares mean · mg/L
Change From Baseline in CRP at Weeks 1, 2, 4, 8, and 12
mg/LMaraviroc 300 mg BID (POC)Placebo (POC)
Week 11.20 ± 1.873.40 ± 2.67
Week 23.14 ± 2.061.81 ± 2.93
Week 43.36 ± 2.34-1.30 ± 3.33
Week 82.33 ± 2.10-1.14 ± 2.98
Week 122.35 ± 2.261.93 ± 3.22
Statistical analysis
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.481 (This analysis was carried out using ANCOVA with CRP as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -2.20 · 90% CI -7.36 to 2.96
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.698 (This analysis was carried out using ANCOVA with CRP as the covariate, treatment, region as fixed effects.) · Mean difference (final values): 1.33 · 90% CI -4.34 to 6.99
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.233 (This analysis was carried out using ANCOVA with CRP as the covariate, treatment, region as fixed effects.) · Mean difference (final values): 4.65 · 90% CI -1.79 to 11.10
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.320 (This analysis was carried out using ANCOVA with CRP as the covariate, treatment, region as fixed effects.) · Mean difference (final values): 3.48 · 90% CI -2.29 to 9.25
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.912 (This analysis was carried out using ANCOVA with CRP as the covariate, treatment, region as fixed effects.) · Mean difference (final values): 0.41 · 90% CI -5.81 to 6.64
SecondaryChange From Baseline in Disease Activity Score Using CRP (DAS28-4[CRP]) at Weeks 1, 2, 4, 8, and 12

DAS28-4 (CRP) was calculated using the following formula: DAS28- 4(CRP) = 0.56 √28 Tender Joint Count + 0.28 √28 Swollen Joint Count + 0.36\*natural logarithm(CRP + 1) + 0.014\*Patient Global Assessment + 0.96. DAS28 provides a number on a scale (0 to 10) indicating current disease activity. A score above 5.1 means high disease activity and a score below 3.2 indicates low disease activity. Change from baseline at each visit was analyzed for DAS28-4 (CRP). The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 DAS28-4 (CRP) data were collected, but not analyzed.

Time frame:
Baseline, Weeks 1, 2, 4, 8, and 12
Reported as:
Least squares mean · mg/L
Change From Baseline in Disease Activity Score Using CRP (DAS28-4[CRP]) at Weeks 1, 2, 4, 8, and 12
mg/LMaraviroc 300 mg BID (POC)Placebo (POC)
Week 1-0.23 ± 0.09-0.17 ± 0.13
Week 2-0.41 ± 0.12-0.33 ± 0.17
Week 4-0.64 ± 0.14-0.65 ± 0.19
Week 8-0.82 ± 0.15-0.51 ± 0.21
Week 12-0.73 ± 0.16-0.63 ± 0.22
Statistical analysis
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.653 (This analysis was carried out using ANCOVA with baseline DAS28-4 (CRP) as the covariate, treatment, country as fixed effects.) · Mean difference (final values): -0.07 · 90% CI -0.31 to 0.18
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.703 (This analysis was carried out using ANCOVA with baseline DAS28-4 (CRP) as the covariate, treatment, country as fixed effects.) · Mean difference (final values): -0.08 · 90% CI -0.41 to 0.26
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.968 (This analysis was carried out using ANCOVA with baseline DAS28-4 (CRP) as the covariate, treatment, country as fixed effects.) · Mean difference (final values): 0.01 · 90% CI -0.37 to 0.39
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.210 (This analysis was carried out using ANCOVA with baseline DAS28-4 (CRP) as the covariate, treatment, country as fixed effects.) · Mean difference (final values): -0.31 · 90% CI -0.72 to 0.10
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.696 (This analysis was carried out using ANCOVA with baseline DAS28-4 (CRP) as the covariate, treatment, country as fixed effects.) · Mean difference (final values): -0.10 · 90% CI -0.53 to 0.33
SecondaryChange From Baseline in Mean Orthostatic Blood Pressure (BP)

Supine BP was recorded after 5 minutes lying down; subjects then sat for 2 minutes then stood for 2 minutes and standing BP was recorded. Orthostatic BP = either a systolic BP drop \> 20 mmHg, or diastolic BP drop \> 10 mmHg and/or drop in systolic BP \< 90 mmHg. If a subject met the orthostatic criteria, they were required to complete 2 additional readings to provide a triplicate reading. The means of replicate BP values were used in the analysis. Baseline = the latest non-missing value from a range of pre-treatment visits. Change from baseline to Week 16 was analyzed for orthostatic BP.

Time frame:
Baseline, 16 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean Orthostatic Blood Pressure (BP)
mmHgMaraviroc 150 mg BID (PK)Maraviroc 300 mg BID (PK)Maraviroc 300 mg BID (POC)Placebo (POC)
Standing Systolic BP20.9 ± 13.1818.0 ± 7.7117.8 ± 11.2517.5 ± 12.36
Supine Systolic BP20.9 ± 13.5818.3 ± 9.5117.5 ± 13.8618.0 ± 11.12
Standing Diastolic BP13.0 ± 4.978.3 ± 5.6511.7 ± 6.9811.5 ± 5.15
Supine Diastolic BP10.3 ± 7.9410.9 ± 5.0812.2 ± 8.1410.8 ± 5.12
PrimaryAmerican College of Rheumatology (ACR) 20% Responders at Week 12

A subject was an ACR 20 responder if: the counts for both tender and swollen joints had reduced by 20% or more from baseline; and 3 out of the following 5 assessments showed reduction of 20% or more from baseline assessment: Patient's Assessment of Arthritis Pain (Visual Analogue Scale \[VAS\]), Patient's Global Assessment of Arthritis (VAS), Physician's Global Assessment of Arthritis (Categorical), Health Assessment Questionnaire - Disability Index (HAQ-DI), and C-Reactive Protein (CRP).

Time frame:
Week 12
Reported as:
Number · Participants
American College of Rheumatology (ACR) 20% Responders at Week 12
ParticipantsMaraviroc 300 mg BID (POC)Placebo (POC)
American College of Rheumatology (ACR) 20% Responders at Week 12216
Statistical analysis
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · Barnard/Pearson chi-square test · p = 0.155 (p-value (one-sided) was based on Barnard exact test if more than 20% of expected cell counts were \< 5 otherwise Pearson chi-square test.) · Percentage difference: 9.09 · 90% CI -6.16 to 21.83Percentage Difference = maraviroc responders divided by the number of maraviroc participants analyzed minus placebo responders divided by the number of placebo participants analyzed.
SecondaryChange From Baseline in Mean Heart Rate

Heart rate = standing and supine at the same time the orthostatic BP measurements were obtained. Baseline was defined to be the latest non-missing value from a range of pre-treatment visits. Means of replicate values were not used.

Time frame:
Baseline, 16 weeks
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in Mean Heart Rate
beats per minute (bpm)Maraviroc 150 mg BID (PK)Maraviroc 300 mg BID (PK)Maraviroc 300 mg BID (POC)Placebo (POC)
Standing Heart Rate14.6 ± 6.738.1 ± 3.6411.8 ± 6.9111.4 ± 8.13
Supine Heart Rate15.0 ± 8.2810.4 ± 4.5611.6 ± 6.069.2 ± 6.16
SecondaryNumber of Subjects With Categorical Absolute Vital Signs and Vital Sign Changes Compared to Baseline

Baseline was defined to be the latest non-missing value from a range of pre-treatment visits. Maximum increase from baseline in supine and standing systolic BP was \> = 30 mmHg, and maximum increase from baseline in supine and standing diastolic BP was \> = 20 mmHg.

Time frame:
Baseline, 16 weeks
Reported as:
Number · Participants
Number of Subjects With Categorical Absolute Vital Signs and Vital Sign Changes Compared to Baseline
ParticipantsMaraviroc 150 mg BID (PK)Maraviroc 300 mg BID (PK)Maraviroc 300 mg BID (POC)Placebo (POC)
Maximum Increase in Supine Systolic BP2143
Maximum Increase in Standing Systolic BP1122
Maximum Increase in Supine Diastolic BP1180
Maximum Increase in Standing Diastolic BP0032
SecondaryChange From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (RR Interval, PR Interval, QRS Complex, QT Interval, Corrected QT [QTc] Interval, QTcB Interval [Bazett's Correction], QTcF Interval [Fridericia's Correction]).

Baseline was defined to be the latest non-missing value from a range of pre-treatment visits. Means of replicate values were used. QTc interval was not measured for the PK populations.

Time frame:
Baseline, 16 weeks
Reported as:
Mean · msec
Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (RR Interval, PR Interval, QRS Complex, QT Interval, Corrected QT [QTc] Interval, QTcB Interval [Bazett's Correction], QTcF Interval [Fridericia's Correction]).
msecMaraviroc 150 mg BID (PK)Maraviroc 300 mg BID (PK)Maraviroc 300 mg BID (POC)Placebo (POC)
RR Interval137.0 ± 79.18114.3 ± 63.38140.0 ± 70.81117.6 ± 48.26
PR Interval19.7 ± 7.1313.0 ± 6.9316.2 ± 8.0015.4 ± 10.47
QRS Complex7.6 ± 4.757.3 ± 4.8911.3 ± 6.5610.2 ± 5.35
QT Interval35.0 ± 19.4722.5 ± 10.6731.9 ± 18.7428.7 ± 13.97
QTc Interval0 ± 00 ± 019.6 ± 17.6920.3 ± 12.75
QTcB Interval23.1 ± 19.7023.3 ± 9.5527.9 ± 18.4730.2 ± 23.88
QTcF Interval22.9 ± 19.6417.3 ± 7.1628.3 ± 18.7729.8 ± 22.20
SecondaryChange From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (Heart Rate).

Baseline was defined to be the latest non-missing value from a range of pre-treatment visits. Means of replicate values were used.

Time frame:
Baseline, 16 weeks
Reported as:
Mean · bpm
Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (Heart Rate).
bpmMaraviroc 150 mg BID (PK)Maraviroc 300 mg BID (PK)Maraviroc 300 mg BID (POC)Placebo (POC)
Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (Heart Rate).11.2 ± 5.828.8 ± 5.7612.0 ± 6.4010.5 ± 4.91
SecondaryNumber of Subjects With Categorical Absolute ECG Parameters and ECG Changes Compared to Baseline

Maximum QTcB, QTcF, and QTc intervals were defined as 450 to \< 480 msec, 480 to \< 500 msec, or \> = 500 msec.

Time frame:
Baseline, 16 weeks
Reported as:
Number · Participants
Number of Subjects With Categorical Absolute ECG Parameters and ECG Changes Compared to Baseline
ParticipantsMaraviroc 150 mg BID (PK)Maraviroc 300 mg BID (PK)Maraviroc 300 mg BID (POC)Placebo (POC)
Maximum QTc Interval 450 to < 480 msec0022
Maximum QTc Interval 480 to < 500 msec0000
Maximum QTc Interval > = 500 msec0000
Maximum QTcB Interval 450 to < 480 msec13138
Maximum QTcB Interval 480 to < 500 msec0021
Maximum QTcB Interval > = 500 msec0001
Maximum QTcF Interval 450 to < 480 msec0295
Maximum QTcF Interval 480 to < 500 msec0000
Maximum QTcF Interval > = 500 msec0000
SecondaryChange From Baseline in Short Form-36 (SF-36) Physical Component Summary at Weeks 4 and 12

The SF-36 v.2 (Acute version) is a 36-item generic health status measure that measures 8 general health concepts: Physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Each domain of the eight domains and the summary concept (physical component score) are scored to yield values between 0 (worst) and 100 (best). Change from baseline at Weeks 4 and 12 were analyzed for SF-36. Due to the termination of the study, SF-36 results for the PK component group were not analyzed.

Time frame:
Baseline, Weeks 4 and 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Short Form-36 (SF-36) Physical Component Summary at Weeks 4 and 12
scores on a scaleMaraviroc 300 mg BID (POC)Placebo (POC)
Week 44.33 ± 0.893.76 ± 1.25
Week 123.14 ± 1.044.81 ± 1.65
Statistical analysis
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.698 (This analysis was carried out ANCOVA with baseline SF-36 score as the covariate, treatment, region as fixed effects.) · Mean difference (final values): 0.57 · 90% CI -1.87 to 3.01
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.344 (This analysis was carried out ANCOVA with baseline SF-36 score as the covariate, treatment, region as fixed effects.) · Mean difference (final values): -1.68 · 90% CI -4.62 to 1.26
SecondaryChange From Baseline in SF-36 Mental Component Summary at Weeks 4 and 12

The SF-36 v.2 (Acute version) \[12\] is a 36-item generic health status measure that measures 8 general health concepts: Physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Each domain of the eight domains and the summary concept (mental component score) are scored to yield values between 0 (worst) and 100 (best). Change from baseline at Weeks 4 and 12 were analyzed for SF-36. Due to the termination of the study, SF-36 results for the PK component group were not analyzed.

Time frame:
Baseline, Weeks 4 and 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline in SF-36 Mental Component Summary at Weeks 4 and 12
scores on a scaleMaraviroc 300 mg BID (POC)Placebo (POC)
Week 41.42 ± 1.250.72 ± 1.75
Week 121.17 ± 1.410.61 ± 2.25
Statistical analysis
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.734 (This analysis was carried out ANCOVA with baseline SF-36 score as the covariate, treatment, region as fixed effects.) · Mean difference (final values): 0.70 · 90% CI -2.71 to 4.11
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · ANCOVA · p = 0.818 (This analysis was carried out ANCOVA with baseline SF-36 score as the covariate, treatment, region as fixed effects.) · Mean difference (final values): 0.56 · 90% CI -3.50 to 4.62
SecondaryNumber of Subjects With Withdrawal From Study Due to Lack of Efficacy

Withdrawal is the total number of withdrawals from the study. Withdrawal due to lack of efficacy was collected based on the investigator's judgement.

Time frame:
16 weeks
Reported as:
Number · participants
Number of Subjects With Withdrawal From Study Due to Lack of Efficacy
participantsMaraviroc 300 mg BID (POC)Placebo (POC)
Overall Withdrawal2214
Withdrawal due to Lack of Efficacy52
Statistical analysis
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · Fisher Exact · p = 0.649
SecondarySurvival Analysis of Time to Withdrawal: Proportion of Subjects Who Did Not Withdraw From the Study Due to Lack of Efficacy.

Withdrawal due to lack of efficacy was collected based on the investigator's judgement. Time to withdrawal was measured by the probability that a subject did not withdraw due to lack of efficacy by a particular visit. This was a statistical estimate (Kaplan-Meier Survival Analysis) of the probability that a participant would not withdraw due to lack of efficacy.

Time frame:
Weeks 1 to 12
Reported as:
Number · proportion
Survival Analysis of Time to Withdrawal: Proportion of Subjects Who Did Not Withdraw From the Study Due to Lack of Efficacy.
proportionMaraviroc 300 mg BID (POC)Placebo (POC)
Week 1 (n=77, 33)1.001.00
Week 2 (n=77, 32)1.001.00
Week 4 (n=76, 32)1.001.00
Week 8 (n=69, 31)0.991.00
Week 12 (n=58, 21)0.930.92
Statistical analysis
  • Maraviroc 300 mg BID (POC) vs Placebo (POC) · Log Rank · p = 0.9826
SecondaryArea Under the Plasma Concentration-Time Profile From Time Zero to Four Hours Postdose (AUC 0-4) for MTX at Screening and Week 1 and Maraviroc at Week 1

Effect of maraviroc on the PK of MTX (comparison of AUC0-4 of MTX at screening versus at Week 1 after coadministration with 150 mg or 300 mg of maraviroc). PK was assessed at screening (MTX) and at Week 1 (maraviroc and MTX).

Time frame:
Screening (1, 2, 3, and 4 hours post-dose), Week 1 (0.5, 1, 2, 3, and 4 hours post-dose)
Reported as:
Geometric mean · ng.hr/mL
Area Under the Plasma Concentration-Time Profile From Time Zero to Four Hours Postdose (AUC 0-4) for MTX at Screening and Week 1 and Maraviroc at Week 1
ng.hr/mLMaraviroc 150 mg BID (PK)Maraviroc 300 mg BID (PK)
Plasma MTX (Screening)909.4 ± 422.37888.9 ± 249.51
Plasma MTX (Week 1)1045.6 ± 329.93844.8 ± 273.92
Plasma Maraviroc (Week 1)451.6 ± 247.331106.8 ± 1029.60
SecondaryMaximum Observed Concentration (Cmax) During the Dosing Interval for MTX at Screening and Week 1 and Maraviroc at Week 1

Effect of maraviroc on the PK of MTX (comparison of Cmax of MTX at screening versus at Week 1 after coadministration with 150 mg or 300 mg of maraviroc). PK was assessed at screening (MTX) and at Week 1 (maraviroc and MTX).

Time frame:
Screening (1, 2, 3, and 4 hours post-dose), Week 1 (0.5, 1, 2, 3, and 4 hours post-dose)
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax) During the Dosing Interval for MTX at Screening and Week 1 and Maraviroc at Week 1
ng/mLMaraviroc 150 mg BID (PK)Maraviroc 300 mg BID (PK)
Plasma MTX (Screening)338.7 ± 143.94352.1 ± 115.72
Plasma MTX (Week 1)403.8 ± 97.46322.8 ± 104.20
Plasma Maraviroc (Week 1)199.59 ± 115.603461.03 ± 365.715
SecondaryTime for Cmax (Tmax) for MTX at Screening and Week 1 and Maraviroc at Week 1

PK was assessed at screening (MTX) and at Week 1 (maraviroc and MTX).

Time frame:
Screening (1, 2, 3, and 4 hours post-dose), Week 1 (0.5, 1, 2, 3, and 4 hours post-dose)
Reported as:
Median · hr
Time for Cmax (Tmax) for MTX at Screening and Week 1 and Maraviroc at Week 1
hrMaraviroc 150 mg BID (PK)Maraviroc 300 mg BID (PK)
Plasma MTX (Screening)2.000 (1.00 to 3.00)1.000 (1.00 to 3.00)
Plasma MTX (Week 1)1.000 (0.50 to 2.00)1.500 (0.50 to 2.00)
Plasma Maraviroc (Week 1)2.000 (0.50 to 3.00)2.500 (1.00 to 4.00)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maraviroc 150 mg BID (PK)—0/8 (0%)4/8 (50%)
Maraviroc 300 mg BID (PK)—0/8 (0%)4/8 (50%)
Maraviroc 300 mg BID (POC)—0/77 (0%)39/77 (50.6%)
Placebo (POC)—0/33 (0%)21/33 (63.6%)
Most frequent other events
Showing 10 of 82
Most frequent other events
EventMaraviroc 150 mg BID (PK)Maraviroc 300 mg BID (PK)Maraviroc 300 mg BID (POC)Placebo (POC)
ArthralgiaMusculoskeletal and connective tissue disorders2/80/80/771/33
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/80/83/778/33
Dry mouthGastrointestinal disorders0/81/81/771/33
NauseaGastrointestinal disorders1/80/84/770/33
FatigueGeneral disorders1/80/83/770/33
SinusitisInfections and infestations0/81/80/771/33
Upper respiratory tract infectionInfections and infestations0/81/83/770/33
Muscle spasmsMusculoskeletal and connective tissue disorders1/81/80/771/33
Nasal congestionRespiratory, thoracic and mediastinal disorders0/81/81/771/33
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/81/81/770/33

Baseline characteristics

Age, Customized
Age, Customized(Participants)Maraviroc 150 mg BID (PK)Maraviroc 300 mg BID (PK)Maraviroc 300 mg BID (POC)Placebo (POC)Total
< 18 years00000
18 to 44 years1015622
45 to 64 years48482181
> = 65 years3014623
Sex: Female, Male
Sex: Female, Male(Participants)Maraviroc 150 mg BID (PK)Maraviroc 300 mg BID (PK)Maraviroc 300 mg BID (POC)Placebo (POC)Total
Female457122102
Male4361124
08

Study locations

44 sites
  • Pfizer Investigational Site
    Huntington Beach, California 92646, United States
  • Pfizer Investigational Site
    San Francisco, California 94115, United States
  • Pfizer Investigational Site
    Hamden, Connecticut 06518, United States
  • Pfizer Investigational Site
    Meriden, Connecticut 06450, United States
  • Pfizer Investigational Site
    New Haven, Connecticut 06510-2716, United States
  • Pfizer Investigational Site
    New Haven, Connecticut 06511-5473, United States
  • Pfizer Investigational Site
    Daytona Beach, Florida 32114, United States
  • Pfizer Investigational Site
    Port Orange, Florida 32127, United States
  • Pfizer Investigational Site
    Savannah, Georgia 31405, United States
  • Pfizer Investigational Site
    Savannah, Georgia 31406, United States
  • Pfizer Investigational Site
    Moline, Illinois 61265, United States
  • Pfizer Investigational Site
    Madisonville, Kentucky 42431, United States
  • Pfizer Investigational Site
    Kalamazoo, Michigan 49007, United States
  • Pfizer Investigational Site
    Kalamazoo, Michigan 49048, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68154, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89128, United States
  • Pfizer Investigational Site
    Syracuse, New York 13210, United States
  • Pfizer Investigational Site
    Hickory, North Carolina 28601, United States
  • Pfizer Investigational Site
    Hickory, North Carolina 28602, United States
  • Pfizer Investigational Site
    Minot, North Dakota 58701, United States
  • Pfizer Investigational Site
    Duncansville, Pennsylvania 16635, United States
  • Pfizer Investigational Site
    Maroochydore, Queensland 4558, Australia
  • Pfizer Investigational Site
    Woodville, South Australia 5011, Australia
  • Pfizer Investigational Site
    Hobart, Tasmania 7001, Australia
  • Pfizer Investigational Site
    Berlin, 10117, Germany
  • Pfizer Investigational Site
    Berlin, 14059, Germany
  • Pfizer Investigational Site
    Leipzig, 04103, Germany
  • Pfizer Investigational Site
    Hyderabad, Andhra Pradesh 500 082, India
  • Pfizer Investigational Site
    Bangalore, Karnataka 560 034, India
  • Pfizer Investigational Site
    Bangalore, Karnataka 560003, India
  • Pfizer Investigational Site
    Genova, 16132, Italy
  • Pfizer Investigational Site
    Pavia, 27100, Italy
  • Pfizer Investigational Site
    Guadalajara, Jalisco 44690, Mexico
  • Pfizer Investigational Site
    Guadalajara, Jalisco CP 44340, Mexico
  • Pfizer Investigational Site
    Coimbra, 3000-075, Portugal
  • Pfizer Investigational Site
    Lisboa, 1600-035, Portugal
  • Pfizer Investigational Site
    Lisbon, 1000-247, Portugal
  • Pfizer Investigational Site
    Santiago de Compostela, A Coruña 15705, Spain
  • Pfizer Investigational Site
    Barcelona, 08035, Spain
  • Pfizer Investigational Site
    Madrid, 28007, Spain
  • Pfizer Investigational Site
    Sevilla, 41014, Spain
  • Pfizer Investigational Site
    Dnipropetrovsk, 49005, Ukraine
  • Pfizer Investigational Site
    Kharkiv, 61000, Ukraine
  • Pfizer Investigational Site
    Simferopol, 95017, Ukraine
09

References and documents

Publications

  • Fleishaker DL, Garcia Meijide JA, Petrov A, Kohen MD, Wang X, Menon S, Stock TC, Mebus CA, Goodrich JM, Mayer HB, Zeiher BG. Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial. Arthritis Res Ther. 2012 Jan 17;14(1):R11. doi: 10.1186/ar3685. PubMed 22251436 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2007
First posted
Jan 29, 2007
Start
Feb 2007
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Feb 5, 2010
Last update
Nov 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00427934
Lead sponsor
Pfizer
First posted
Jan 29, 2007
Start date
Feb 2007
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Feb 5, 2010
Last update
Nov 5, 2014

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maraviroc

Start the discussion